Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seres Therapeutics Inc
(NQ:
MCRB
)
0.8742
+0.0042 (+0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seres Therapeutics Inc
< Previous
1
2
3
4
Next >
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
September 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
September 07, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 03, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
July 28, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
June 30, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
June 07, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
May 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
May 10, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
April 28, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
March 18, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit
February 22, 2022
From
Seres Therapeutics
Via
Business Wire
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
February 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
February 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
January 24, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
January 19, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
December 16, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
November 30, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 24, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
November 10, 2021
From
Seres Therapeutics
Via
Business Wire
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
November 04, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
October 26, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
October 02, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
September 29, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
September 15, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.